Novo Nordisk Reports Strong Q3 Results with Wegovy Sales Surpassing Expectations

Novo Nordisk's Q3 sales were DKK 58.73 billion, against an expected DKK 57.80 billion.
Q3 Sales of Weight-Loss Drug Wegovy Reach 9.65 Billion Danish Kroner, Exceeding Expectations of 8.07 Billion Danish Kroner.
Pre-tax profit in the third quarter was DKK 280.6 billion, compared to an expected DKK 266.8 billion.
EBIT in the third quarter was DKK 269.1 billion, against an expected DKK 254.2 billion.
Third-quarter net revenue 224.8 billion Danish kroner, expected to be 214.9 billion Danish kroner.